ERBB2 and breast cancer: Trials are currently evaluating the effects of preoperative pembrolizumab combined with neoadjuvant chemotherapy (paclitaxel, carboplatin, cyclophosphamide, doxorubicin, and/or capecitabine) for TNBC or HR+, HER2- breast cancer (NCT04443348), in addition to radiotherapy combined with chemotherapy (nab-paclitaxel and paclitaxel) and pembrolizumab in PD-L1+ TNBC (NCT05233696).